Open AccessPB2356 IMPACT OF ABO BLOOD GROUP INCOMPATIBILITY ON THE OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Author(s) -
Çiftçiler R.,
Goker H.,
Buyukasık Y.,
Aksu S.,
Demiroglu H.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000567888.22986.a4
Subject(s) - abo blood group system , medicine , contraindication , hematopoietic stem cell transplantation , transplantation , gastroenterology , immunology , pathology , alternative medicine
Background: Impact of ABO Blood Group Incompatibility on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation Aims: ABO and Rh compatibility are not required between the donor and recipient for alloHSCT. Although ABO incompatibility is not considered a contraindication in HSCT, its clinical outcomes are still a doubtful. In this study, we analyzed the neutrophil and platelet recovery, GVHD, relapse rate, mortality rate, non‐relapse mortality and survival in patients who underwent alloHSCT. Methods: Two hundred and sixty eight patients with hematopoietic malign diseases and inborn errors of metabolism or the immune system who received an alloHSCT in our HSC transplant center between the years of 2001 and 2018 were evaluated. Results: There were 264 (98.5%) matched sibling, and 4 (1.5%) haploidentic transplants. Indications for HSCT included both hematological malignancies (n = 261) and benign conditions (n = 7). Of these donor recipient pairs, there were 193 (72%) matches, 36 (13.4%) major, 29 (10.8%) minor and 10 (3.7%) bidirectional ABO mismatches. The median follow‐up of 120 months (range, 6‐213) for the entire group. The OS and DFS were not statistically significant different between two groups. The seventy one (41.1%) of the ABO match patients and 27 (35.5%) of the ABO mismatch patients developed GvHD. There was no significant difference between the two groups in terms of GvHD (p = 0.86). The median neutrophil engraftment day was 11 (7‐20) day in ABO match patients and 11 (7‐19) day in ABO mismatch patients (p = 0.44). The median platelet engraftment day was 12 (8‐38) day in ABO match patients and 12 (8‐40) day in ABO mismatch patients (p = 0.48). Summary/Conclusion: In conclusion, this study showed major ABO incompatibility does not lead mainly to delayed RBC recovery, platelet engraftment and neutrophil engraftment after alloHSCT. Major ABO mismatch does not seem to have a significant effect on other major outcomes after alloHSCT, such as GVHD, relapse rate, mortality rate, non‐relapse mortality rate, DFS and OS.